Q-omics provides the consensus-scored GPR6 profile across patient tissues and cancer cell-line models. GPR6 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GPR6 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, GPR6 RNA expression shows 7,657 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, BRCA, and TGCT as cancer lineages where GPR6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR6 survival associations across molecular data types. GPR6 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR6 RNA expression–survival associations across cancer types. High GPR6 expression shows unfavorable associations in LIHC, LUAD and COAD, but favorable associations in UCEC, PAAD and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LIHC as the clearest survival context for GPR6 RNA expression.
This table summarizes GPR6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPR6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR6 shows lower tumor expression in ESCA and higher tumor expression in BRCA, BLCA, UCEC and LUSC. The BRCA box plot shows higher GPR6 RNA expression in tumor versus normal tissue (log2 FC = +0.105, t-test p = .040).
This table shows molecular features associated with GPR6 in patient tissues and cancer cell lines. In patient samples, GPR6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
